SCHEMBL6590974

SCHEMBL6590974

CC(C)(CC(N)=O)CC(C(=O)NC1C(=O)COC1CN1CCCC1)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 7/20 0.38
CTSS P25774 7/20 0.38
CTSK P43235 7/20 0.38
KCNQ2 O43526 2/20 0.35
CCR1 P32246 1/20 0.35
CCR8 P51685 1/20 0.34
RAB9A P51151 2/20 0.33
MITF O75030 2/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HTT P42858 1/20 0.33
GFER P55789 1/20 0.33
PAX8 Q06710 1/20 0.33
ATM Q13315 1/20 0.33
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
HIF1A Q16665 1/20 0.32
KCNQ3 O43525 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6592014 0.88 CTSL (0.48) CTSLCTSSCTSK
SCHEMBL6591371 0.87 CTSL (0.41) CTSLCTSSCTSK
SCHEMBL6590482 0.86 CCR1 (0.36) CTSLCTSSCTSKKCNQ2CCR1
SCHEMBL6476921 0.84 CTSL (0.39) CTSLCTSSCTSKCCR1RAB9A
SCHEMBL6590366 0.83 CTSL (0.39) CTSLCTSSCTSK
SCHEMBL6477176 0.81 CTSL (0.36) CTSLCTSSCTSK
SCHEMBL6587766 0.79 CTSL (0.31) CTSLCTSSCTSK
SCHEMBL6590154 0.78 CYP2C19 (0.34) CTSLCTSSCTSKCCR1LMNA
SCHEMBL6590381 0.77
SCHEMBL7527408 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1413580-A1 Furanone derivatives as inhibitors of Cathepsin S Medivir UK Ltd (GB) 2004-04-28 EP claimed
EP-1178986-B1 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S MEDIVIR UK LTD (GB) 2004-02-25 EP claimed
US-20030203900-A1 Cysteine protease inhibitors MEDIVIR UK LTD (GB) 2003-10-30 US claimed
JP-2002544274-A 2002-12-24 JP claimed
EP-1178986-A2 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S Medivir UK Ltd (GB) 2002-02-13 EP claimed
WO-2000069855-A2 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S MEDIVIR UK LIMITED (GB) 2000-11-23 WO claimed
EP-1413580-A1 Furanone derivatives as inhibitors of Cathepsin S Medivir UK Ltd (GB) 2004-04-28 EP disclosed
EP-1178986-B1 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S MEDIVIR UK LTD (GB) 2004-02-25 EP disclosed
US-20030203900-A1 Cysteine protease inhibitors MEDIVIR UK LTD (GB) 2003-10-30 US disclosed
EP-1178986-A2 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S Medivir UK Ltd (GB) 2002-02-13 EP disclosed
WO-2000069855-A2 FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S MEDIVIR UK LIMITED (GB) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203900-A1 Cysteine protease inhibitors CTSS, CTSE, CTSV CTSL 11/4885CTSS 1/4885CTSK 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.